Lynparza 150 Mg 112 Film Coated Tab

Product Description:

• Lynparza contains the active substance olaparib. 
• Olaparib is a cancer medicine called a PARP (poly [adenosine diphosphate-ribose] polymerase inhibitor).
• PARP inhibitors can destroy cancer cells that are poor at repairing DNA damage. 

These specific cancer cells can be identified by:

• Response to chemotherapy (cytotoxin) containing platinum, or
• To look for faulty dna repair genes, such as brca (a breast cancer gene)

What Lynparza is used for:

Lynparza is used to treat:

• A type of ovarian cancer ( BRCA -mutated) that has responded to the first standard treatment with platinum-containing chemotherapy.
• A test is used to find out if you have BRCA -mutated ovarian cancer.

Ovarian cancer that has come back:

• It is used when previous standard treatment with chemotherapy containing platinum has worked on the cancer .
• A type of ovarian cancer (HRD-positive defined by a BRCA mutation or genomic instability) that has responded to the first standard treatment with chemotherapy containing platinum and bevacizumab. 
• Lynparza is used together with bevacizumab.
• A type of breast cancer (BRCA-mutated, HER2-negative) where the cancer has not spread to other parts of the body and where treatment will be given after surgery (treatment after surgery is called adjuvant treatment). 
• You should have received chemotherapy before or after the operation.
• If the cancer is hormone receptor-positive, the doctor may also prescribe hormone therapy.
• A test is used to find out if you have BRCA-mutated breast cancer .

A type of breast cancer ( BRCA -mutated HER2-negative) that has spread from the original tumor:

• You should have received chemotherapy either before or after the cancer has spread.
• A test is used to find out if you have BRCA- mutated breast cancer .
• A type of pancreatic cancer ( BRCA -mutated) that has responded to the first standard treatment with platinum-containing chemotherapy.
• A test is used to find out if you have BRCA -mutated pancreatic cancer.
• A type of prostate cancer (BRCA-mutated) that has spread beyond the original tumor and no longer responds to medical or surgical treatment to reduce testosterone levels. 
• You should have received certain hormonal treatments, such as enzalutamide or abiraterone acetate.
• A test is used to find out if you have BRCA-mutated prostate cancer.
• When Lynparza is given in combination with other cancer medicines, it is important that you also read the package insert for the other medicines. 
• Talk to your doctor if you have any questions about these medicines.

How To Use:

• Always use this medicine exactly as your doctor, pharmacist or nurse has told you. 
• Contact a doctor, pharmacist or nurse if you are unsure.

How to take this medicine:

• Swallow Lynparza tablets whole, with or without food
• Take Lynparza once in the morning and once in the evening
• Do not chew, crush, dissolve or split the tablets. This can affect how quickly the medicine enters your body

How much to take:

• Your doctor will tell you how many tablets of Lynparza to take. It is important that you take the full recommended dose every day.
•  Continue to do so as long as your doctor, pharmacist or nurse has told you
• The usual recommended dose is 300 mg (2 tablets of 150 mg) twice a day - a total of 4 tablets each day

Your doctor may prescribe a different dose if:

• You have kidney problems. You will be asked to take 200 mg (2 tablets of 100 mg) twice a day – a total of 4 tablets each day
• You are taking certain medicines that may affect Lynparza.
• You get certain side effects while using Lynparza. 
• Your doctor may lower the dose or stop the treatment, either for a short period or permanently
• If you take too much Lynparza:
• Contact a doctor or the nearest hospital immediately if you take more Lynparza than your usual dose.

If you have forgotten to take Lynparza:

• If you forget to take Lynparza, take your next regular dose at the scheduled time. 
• You should not take a double dose (two doses at the same time) to replace a missed dose.
• Ask your doctor, pharmacist or nurse if you have any questions about the use of this medicine.

Warnings And Precautions:

Do not use Lynparza:

• If you are allergic to olaparib or any of the other ingredients of this medicine.
• If you are breastfeeding (see below for more information).
• Do not use Lynparza if any of the above applies to you. 
• Talk to your doctor, pharmacist or nurse before taking Lynparza if you are unsure.

Talk to your doctor, pharmacist or nurse before or during treatment with Lynparza:

• If you have a low number of blood cells during tests. 
• This can be a low number of red or white blood cells or a low number of platelets
• For more information about these side effects, including signs and symptoms to look out for (eg fever or infection , bruising or bleeding). 
• In rare cases, this may be a sign of more serious problems with the bone marrow, such as 'myelodysplastic syndrome' (mds) or ' acute myelogenous leukemia ' (aml).
• If you experience any new or worsening symptoms such as difficulty breathing, coughing or heavy breathing. 
• A small number of patients treated with lynparza reported inflammation of the lungs ( pneumonitis ). 
• Pneumonitis is a serious condition that can often require hospital treatment.
• Talk to your doctor, pharmacist or nurse, before or during treatment with Lynparza, if you think that any of this applies to you.

Try and check:

• Your doctor will check your blood before and during treatment with Lynparza.
• You will give a blood sample.

Before treatment:

• Every month during the first year of treatment
• At regular intervals according to the doctor's decision after the first year of treatment.
• If your blood cell count drops to a low level, you may need a blood transfusion (where you get new blood or a blood-based product from a donor).

Taking Lynparza together with drink:

• Avoid drinking grapefruit juice while being treated with Lynparza. It can affect the effect of the medicine.

Contraception, pregnancy and breastfeeding:

Female patients:

• You should not use Lynparza if you are pregnant or may become pregnant. 
• This is because it can harm the unborn child.
• You should not become pregnant while taking this medicine.
• If you have intercourse, you should use two safe methods of contraception while taking this medicine, and for 6 months after taking the last dose of Lynparza.
• It is not known whether Lynparza affects the effectiveness of certain hormonal contraceptives. 
• Talk to your doctor if you are taking a hormonal contraceptive, as your doctor may recommend that you use a non-hormonal contraceptive in addition.
• You should take a pregnancy test before starting Lynparza, regularly during treatment, and
  6 months after taking the last dose of Lynparza. 
• If you become pregnant during this time, you must talk to your doctor immediately.
  It is not known whether Lynparza is excreted in breast milk. 
• You should not breast-feed if you take Lynparza and for 1 month after taking the last dose of Lynparza.
• Talk to your doctor if you plan to breastfeed.

Male patients:

• You must use a condom during sexual activity with a female partner, even if she is pregnant, while receiving Lynparza and for 3 months after the last dose.
• It is not known whether Lynparza passes into the semen.
• Your female partner must also use suitable contraception.
• You should not donate sperm when you receive Lynparza and for 3 months after the last dose.

Driving and using machines:

Lynparza can affect the ability to drive and use machines. 

• Do not drive or use tools or machines if you feel dizzy, weak or tired while taking Lynparza.

Information on other ingredients in this medicine:

• This medicinal product contains less than 1 mmol sodium (23 mg) per 100 mg or 150 mg tablet, and is virtually 'sodium-free'.

Ingredints:

The active substance is olaparib.

• Each Lynparza 150 mg film-coated tablet contains 150 mg olaparib.

What Lynparza looks like and contents of the pack:

• Lynparza 150 mg tablets are green to grey-green, oval, biconvex tablets, debossed with "OP150" on one side and plain on the other.